Share on StockTwits

bluebird bio (NASDAQ:BLUE) CEO Nick Leschly unloaded 22,283 shares of the stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $39.86, for a total value of $888,200.38. Following the transaction, the chief executive officer now directly owns 333,301 shares in the company, valued at approximately $13,285,378. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of bluebird bio (NASDAQ:BLUE) traded up 2.86% on Thursday, hitting $39.95. 244,442 shares of the company’s stock traded hands. bluebird bio has a 52-week low of $17.03 and a 52-week high of $41.75. The stock’s 50-day moving average is $29.84 and its 200-day moving average is $24.14. The company’s market cap is $979.2 million.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.12. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.23 million. Analysts expect that bluebird bio will post $-1.78 EPS for the current fiscal year.

A number of analysts have recently weighed in on BLUE shares. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of bluebird bio in a research note on Wednesday, June 18th. They now have a $53.00 price target on the stock, up previously from $44.00. Separately, analysts at Wedbush raised their price target on shares of bluebird bio to $51.00 in a research note on Monday, June 16th. Finally, analysts at Piper Jaffray initiated coverage on shares of bluebird bio in a research note on Friday, June 13th. They set an “overweight” rating on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $42.48.

bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.